Lumos Receives US FDA Clearance for FebriDx®

MELBOURNE, Australia, July 3, 2023 /PRNewswire/ -- Lumos Diagnostics (ASX: LDX), ("Lumos" or the "Company") a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce that it has received clearance from the US Food and Drug Administration (FDA) to market its FebriDx® r...